NPPA slaps Novartis with Rs 300 crore penalty for over pricing of Voveran: Report

13 Oct 2014 Evaluate

National Pharmaceutical Pricing Authority (NPPA) has reportedly imposed a penalty of around Rs 300 crore on Novartis for over pricing its popular painkilling medicine Voveran. The company has also received a show cause notice to explain in two weeks why action should not be taken against it for overcharging.

Novartis India is engaged in manufacturing and marketing of drugs, pharmaceutical products and formulations for consumer healthcare and animal healthcare.

Novartis Share Price

785.60 -1.65 (-0.21%)
26-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Redington 271.15
Adani Enterprises 2231.85
Amrapali Industries 14.81
Rashi Peripheral 357.00
PDS 366.45
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×